Description

Tadalafil

PDE-5 Inhibitor Research Compound

Tadalafil is a long-acting phosphodiesterase type 5 (PDE-5) inhibitor widely studied for its effects on nitric oxide–mediated signaling, vascular smooth muscle relaxation, and blood flow. Compared with shorter-acting PDE-5 inhibitors, tadalafil is distinguished by its extended duration of action and relatively long elimination half-life.

How Tadalafil Works

Tadalafil selectively inhibits the PDE-5 enzyme, which normally breaks down cyclic guanosine monophosphate (cGMP). By reducing cGMP degradation, tadalafil can enhance and prolong nitric oxide–dependent signaling in vascular smooth muscle.

This mechanism has made tadalafil an important compound in research involving:

• PDE-5 inhibition
• Nitric oxide and cGMP signaling
• Vascular smooth muscle relaxation
• Blood-flow and endothelial research
• Pulmonary vascular physiology
• Lower urinary tract and prostate physiology

Key Characteristics

Long Half-Life
Tadalafil has an elimination half-life of approximately 17.5 hours, substantially longer than several other PDE-5 inhibitors.

Extended Activity
Its long half-life allows pharmacological effects to persist considerably longer than those of shorter-acting compounds in the same class.

High PDE-5 Selectivity
Tadalafil has a strong affinity for PDE-5, making it useful for studying pathways involving cGMP regulation and vascular function.

Well-Characterized Compound
Tadalafil has been extensively investigated in clinical and pharmacological literature, providing researchers with a substantial body of published data.

Research Areas

Tadalafil has been investigated in research related to:

• Nitric oxide signaling
• cGMP metabolism
• Endothelial and vascular function
• Smooth-muscle physiology
• Pulmonary circulation
• Exercise and blood-flow physiology
• Erectile physiology
• Benign prostatic hyperplasia (BPH)
• PDE-5 enzyme activity

Notice & Acknowledgement